Literature DB >> 32476963

Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis.

Mike Oliver Becker1,2, Mislav Radic1,3, Katrin Schmidt4, Dörte Huscher5, Arne Riedlinger4,6, Marissa Michelfelder4,7, Christian Meisel8, Ralf Ewert9, Gerd-Rüdiger Burmester4, Gabriela Riemekasten10.   

Abstract

OBJECTIVE: To identify serum cytokines which predict mortality and/or disease progression in patients with systemic sclerosis, especially with pulmonary involvement.
METHODS: Serum cytokines (IL-6, IL-7, IL-8, IL-10, CCL2, CCL4, TGF-β, TNF-α) were measured in 125 SSc patients, who were recruited and observed in our outpatient clinic. Of these, 60 had pulmonary involvement, classified as either interstitial lung disease (ILD, 43 patients), pulmonary arterial hypertension (PAH, 7 patients) or pulmonary hypertension and ILD (PH-ILD, 10 patients). The association of serum cytokines with clinical features was analysed and their correlation with BAL cytokines measured in a subset of SSc patients with ILD.
RESULTS: Serum cytokines were detected at different levels: high (TGF-β, median 287.5 pg/ml; CCL2, median 89.7 pg/ml; CCL4, median 104.2 pg/ml), low (IL-6, median 3.2 pg/ml; IL-7 median 2.3 pg/ml; IL-8, median 5.2 pg/ml; TNF-α, median 0 pg/ml but with a bimodal distribution) and very low (IL-10, median 0.4 pg/ml). IL-6 and IL-7 were predictive for death in a Cox regression analysis in all SSc patients as well as in all patients with pulmonary involvement; IL-6 was predictive for mortality in SSc-ILD patients. In a multivariate analysis, cytokine levels could also predict a change in lung function, e.g. IL-7 was a predictor for a decline of diffusion capacity (DLCO) by 20 or 30% in ILD patients. In a subset of ILD patients, serum cytokines were compared to BAL cytokines, but revealed only few correlations.
CONCLUSION: In conclusion, the analysis of serum cytokines implicates a role as biomarkers, distinct from BAL. Copyright:
© 2019.

Entities:  

Keywords:  chemokines; cytokines; lung involvement; survival; systemic sclerosis

Mesh:

Substances:

Year:  2019        PMID: 32476963      PMCID: PMC7247092          DOI: 10.36141/svdld.v36i4.7612

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  34 in total

Review 1.  The pathogenesis of systemic sclerosis.

Authors:  Tamiko R Katsumoto; Michael L Whitfield; M Kari Connolly
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

2.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

3.  Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension.

Authors:  Eileen Hsu; Haiwen Shi; Rick M Jordan; James Lyons-Weiler; Joseph M Pilewski; Carol A Feghali-Bostwick
Journal:  Arthritis Rheum       Date:  2011-03

4.  CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.

Authors:  Antje Prasse; Dmitri V Pechkovsky; Galen B Toews; Markus Schäfer; Stephan Eggeling; Corinna Ludwig; Martin Germann; Florian Kollert; Gernot Zissel; Joachim Müller-Quernheim
Journal:  Arthritis Rheum       Date:  2007-05

Review 5.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Authors:  Gabriela Kania; Michal Rudnik; Oliver Distler
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

6.  An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis.

Authors:  Veronica Codullo; Helen M Baldwin; Mark D Singh; Alasdair R Fraser; Catherine Wilson; Ashley Gilmour; Axel J Hueber; Claudia Bonino; Iain B McInnes; Carlomaurizio Montecucco; Gerard J Graham
Journal:  Ann Rheum Dis       Date:  2011-02-01       Impact factor: 19.103

7.  Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients.

Authors:  Jeannine Günther; Angela Kill; Mike Oliver Becker; Harald Heidecke; Judith Rademacher; Elise Siegert; Mislav Radić; Gerd-Rüdiger Burmester; Duska Dragun; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2014-03-11       Impact factor: 5.156

8.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

9.  Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

Authors:  Angelo De Lauretis; Piersante Sestini; Panagiotis Pantelidis; Rachel Hoyles; David M Hansell; Nicole S L Goh; Christopher J Zappala; Dina Visca; Toby M Maher; Christopher P Denton; Voon H Ong; David J Abraham; Peter Kelleher; Laureen Hector; Athol U Wells; Elisabetta A Renzoni
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

10.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Authors:  Dinesh Khanna; Christopher P Denton; Celia J F Lin; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Helen Spotswood; Laura Burke; Jeffrey Siegel; Angelika Jahreis; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2017-10-24       Impact factor: 19.103

View more
  1 in total

Review 1.  Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.

Authors:  Soumya Chatterjee; Apostolos Perelas; Ruchi Yadav; Donald F Kirby; Amandeep Singh
Journal:  Clin Rheumatol       Date:  2022-10-21       Impact factor: 3.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.